ESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-producing Enterobacterales infections
・Real world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 8...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Shionogi
- Region
- Japan
- Scope
- Industry
- Published
- April 8, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
・Real world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 8...
Source route
Continue on shionogi.com
Leave the platform to read the original full article on the publisher site.
Source: Shionogi
Scope: Industry
Related coverage